A trial of PSMA-targeted therapy for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug combination that uses a radioactive molecule to find and treat prostate cancer cells that have spread and are no longer responding to hormone therapy. It may be an option for men with a specific protein called PSMA on their cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 18 or older with prostate cancer that has spread and is no longer controlled by hormone therapy.
- You must have tried at least one newer hormone drug and possibly chemotherapy, or you cannot tolerate chemotherapy.
- Your cancer must show the PSMA protein on a special scan.
- You must have measurable tumors (by scans) or at least one bone metastasis.
- You must have good organ function, including blood counts, liver, and kidneys.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
This trial compares two ways of giving a radioactive drug (177Lu-PSMA-617) designed to find and destroy prostate cancer cells. It tests whether adjusting the dose based on your individual tumor’s activity works better than a fixed standard dose.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Hear when a new Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.